Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis

Cystinosis Clinical Trial

Official title:

A Randomized, Crossover Pharmacokinetic and Pharmacodynamic Study to Determine the Safety and Efficacy of Cysteamine Bitartrate Delayed-release Capsules (RP103), Compared to Cystagon® in Patients With Nephropathic Cystinosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01000961
• Other study ID #: RP103-03
• Status: Completed
• Phase: Phase 3
• First received: October 22, 2009
• Last updated: January 13, 2017
• Start date: June 2010
• Est. completion date: August 2011

Study information

• Verified date: January 2017
• Source: Horizon Orphan LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Cystinosis is an inherited disease that if untreated, results in kidney failure as early as the first decade of life. The current marketed therapy is Cystagon® (cysteamine bitartrate) which must be taken every six hours for the rest of the patient's life to prevent complications of cystinosis. RP103 is a formulation of cysteamine bitartrate that is being studied to see if it may be able to be given less frequently, once every 12 hours, and have similar results to four times a day Cystagon®.

Description:

This is a multi-center, open-label, randomized, cross-over study to determine whether steady-state, twice a day treatment with Cysteamine Bitartrate Delayed-release Capsules(RP103) results in comparable depletion of white blood cell (WBC) cystine levels compared to the existing four times a day cysteamine treatment. It will involve up to 20 clinic visits plus intermittent home use of the RP103. Most of these clinic visits occur in clusters of 3-4 consecutive days. Eligible patients will be offered enrollment into a long-term follow up study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 43
• Est. completion date: August 2011
• Est. primary completion date: June 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years and older

Eligibility

Inclusion Criteria:

• Male and female subjects must have nephropathic cystinosis.

• Subjects must be on a stable dose of Cystagon® sufficient to maintain their white blood cell (WBC) cystine level at = 1.0 nmol/half-cystine/mg protein.

• Subjects must be able to swallow their typically administered Cystagon® capsule with the capsule intact.

• Within the last 6 months, no clinically significant change in liver function [i.e., ALT, AST, total bilirubin] and renal function [i.e., estimated GFR] at Screening as determined by the Investigator.

• Subjects with an estimated GFR (corrected for body surface area) > 30 mL/min/1.73m2.

• Sexually active female subjects of childbearing potential (i.e., not surgically sterile [tubal ligation, hysterectomy, or bilateral oophorectomy] or at least 2 years naturally postmenopausal) must agree to utilize the same acceptable form of contraception from Screening through completion of the study.

• Subjects must be willing and able to comply with the study restrictions and requirements.

• Subjects or their or their parent or guardian must provide written informed consent and assent (where applicable) prior to participation in the study.

Exclusion Criteria:

• Subject's age < 6 years old or subject's weight < 21 kg.

• Subjects with a known history, currently of the following conditions or other health issues that make it, in the opinion of the investigator, unsafe for them to participate: inflammatory bowel disease (if currently active) or have had prior resection of small intestine; Heart disease (e.g., myocardial infarction, heart failure, arrhythmias or poorly controlled hypertension) 90 days prior to Screening; Active bleeding disorder 90 days prior to Screening; Malignant disease within the last 2 years.

• Patients with a hemoglobin level < 10 g/dL at Screening or a level that, in the opinion of the investigator, makes it unsafe for the subject to participate.

• Subjects receiving any form of cysteamine medication through a gastric tube.

• Subjects who are receiving maintenance dialysis or who have had a kidney transplant.

• Subjects who are on an active kidney transplant list or who are planning to receive a kidney transplant within 3 months of Screening.

• Subjects with known hypersensitivity to cysteamine or penicillamine.

• Female subjects who are nursing, planning a pregnancy, known or suspected to be pregnant, or have a positive serum pregnancy screen.

• Subjects who have a made a blood donation within 30 days of Screening.

• Subjects who, in the opinion of the Investigator, are not able or willing to comply with the protocol.

Related Conditions & MeSH terms

• Cystinosis
• Fanconi Syndrome

Intervention

Drug:
• Cystagon® (Cysteamine Bitartrate)
Run-in Period (Weeks 1, 2, 3) and Period 1 (Weeks 4, 5, 6) or Period 2 (Weeks 7, 8, 9); Immediate crossover to opposite treatment than taken during Period 1: Every 6H, supplied in 150 and 50mg capsules/Duration of Treatment: 3 weeks each period used
• Cysteamine Bitartrate Delayed-release Capsules (RP103)
Period 1 (Weeks 4, 5, 6) or Period 2 (Weeks 7, 8, 9); Immediate crossover to opposite treatment than taken during Period 1: Every 12H, supplied in 75 and 25mg capsules/Duration of Treatment: 3 weeks

Locations

Country	Name	City	State
France	Hospices Civils de Lyon	Lyon
France	Villeneuve-Lapeyronie Hospital	Montpellier
France	Necker Hospital	Paris
France	Robert Debre Hospital	Paris
Netherlands	Radboud University Nijmegen Medical Center	Nijmegen
United States	Emory Children's Center	Atlanta	Georgia
United States	Ann & Robert H. Lurie Children's Hospital of Chicago (formerly Children's Memorial Hospital)	Chicago	Illinois
United States	Stanford University Medical School	Stanford	California

Sponsors (1)

Lead Sponsor	Collaborator
Horizon Orphan LLC

Countries where clinical trial is conducted

United States,  France,  Netherlands, 

References & Publications (3)

Dohil R, Fidler M, Barshop BA, Gangoiti J, Deutsch R, Martin M, Schneider JA. Understanding intestinal cysteamine bitartrate absorption. J Pediatr. 2006 Jun;148(6):764-9. — View Citation

Fidler MC, Barshop BA, Gangoiti JA, Deutsch R, Martin M, Schneider JA, Dohil R. Pharmacokinetics of cysteamine bitartrate following gastrointestinal infusion. Br J Clin Pharmacol. 2007 Jan;63(1):36-40. — View Citation

Levtchenko EN, van Dael CM, de Graaf-Hess AC, Wilmer MJ, van den Heuvel LP, Monnens LA, Blom HJ. Strict cysteamine dose regimen is required to prevent nocturnal cystine accumulation in cystinosis. Pediatr Nephrol. 2006 Jan;21(1):110-3. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Steady-state White Blood Cell Cystine Levels of RP103 Compared to Cystagon®		4 weeks after the last subject has completed the study
Secondary	Comparison of Cysteamine PK Profiles, Steady State Cmax, Between RP103 and Cystagon®.		4 weeks after the last subject has completed the study
Secondary	Comparison of Cysteamine PK Profiles, Steady State Tmax, Between RP103 and Cystagon®.		4 weeks after the last subject has completed the study
Secondary	Comparison of Cysteamine PK Profiles, AUC(0-t), Between RP103 and Cystagon®.		6 hours post dosing for Cystagon®; 12 hours post dosing for RP103.

External Links

•   RP103 (marketed as PROCYSBI) is now approved by the US FDA for management of nephropathic cystinosis in patients 6 years and older